(CercleFinance.com) – Bayer announces that Asklepios BioPharmaceutical, an independent subsidiary of Bayer, has appointed Mansuo Shannon as Chief Scientific Officer (CSO) of the company.
Mansuo Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, where she also served as CSO.
Reporting to Gustavo Pesquin, Managing Director, Mansuo Shannon will be a member of AskBio’s management team and will lead the R&D organization.
Co-founder and former Chief Scientific Officer R. Jude Samulski remains a member of AskBio’s board of directors.
“As a seasoned pharmaceutical and biotechnology executive who has worked across an impressive range of therapeutic modalities, his experience will be invaluable as our company continues to advance as a leader in gene therapy,” said Gustavo Pesquin.
‘I am confident that Mansuo’s extensive experience in the field of neurodevelopmental and neurodegenerative diseases, in particular, will bring us closer to our strategic vision of creating a new reality for people with diseases for which there is not yet a cure. effective treatment.’
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
